Expression of FLRT3 on the cell surface of renal cancer suggests that blockade of the FLRT3-UNC5B pathway has the potential to benefit patients that are not effectively treated with existing immunotherapies (6, 33, 34, 45–48). Here, FLRT3 is linked to renal carcinoma.